The Role of TNF-α in Alzheimer’s Disease: A Narrative Review
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
This review analyzes the role of TNF-α and its increase in biological fluids in mild cognitive impairment, and Alzheimer’s disease (AD). The potential inhibition of TNF-α with pharmacological strategies paves the way for preventing AD and improving cognitive function in people at risk for dementia. We conducted a narrative review to characterize the evidence in relation to the involvement of TNF-α in AD and its possible therapeutic inhibition. Several studies report that patients with RA and systemic inflammatory diseases treated with TNF-α blocking agents reduce the probability of emerging dementia compared with the general population. Animal model studies also showed interesting results and are discussed. An increasing amount of basic scientific data and clinical studies underscore the importance of inflammatory processes and subsequent glial activation in the pathogenesis of AD. TNF-α targeted therapy is a biologically plausible approach for cognition preservation and further trials are necessary to investigate the potential benefits of therapy in populations at risk of developing AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive Review on Alzheimer’s Disease: Causes and Treatment
Breijyeh, Z., & Karaman, R. (2020) · Molecules · doi:10.3390/molecules25245789 · Cited by 2,789 · cited 1×
“Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that represents the most common cause of dementia in the elderly [1].”
BackgroundImmune attack: the role of inflammation in Alzheimer disease
Heppner, F. L., Ransohoff, R. M., & Becher, B. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3880 · Cited by 2,134 · cited 2×
“However, recent genetic investigations in late-onset AD indicate the involvement of microglia-and astrocyte-related pathways together with the activation of multiple immune pathways in the very early stages of the disease [6,10,11,83–88].”
BackgroundMicroglia in Alzheimer’s disease
Hansen, D. V., Hanson, J. E., & Sheng, M. (2018) · Journal of Cell Biology · doi:10.1083/jcb.201709069 · Cited by 1,935
RIP3, an Energy Metabolism Regulator That Switches TNF-Induced Cell Death from Apoptosis to Necrosis
Zhang, D.-W., Shao, J., Lin, J., Zhang, N., Lu, B.-J., Lin, S.-C., Dong, M.-Q., & Han, J. (2009) · Science · doi:10.1126/science.1172308 · Cited by 1,931 · cited 1×
“TNFR1-mediated cell death involves a switch between caspase-induced apoptosis and necrosis, with key signaling molecules such as receptor-interacting protein 1 (RIP1) and RIP3 identified in TNF-induced programmed necrosis or necroptosis [71,72].”
BackgroundMicroglia in neurodegenerative diseases: mechanism and potential therapeutic targets
Gao, C., Jiang, J., Tan, Y., & Chen, S. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01588-0 · Cited by 1,616
Systemic inflammation and disease progression in Alzheimer disease
Holmes, C., Cunningham, C., Zotova, E., Woolford, J., Dean, C., Kerr, S., Culliford, D., & Perry, V. H. (2009) · Neurology · doi:10.1212/wnl.0b013e3181b6bb95 · Cited by 1,139 · cited 1×
“A 6-month study exploring the association between TNF-α levels and cognitive performance in 300 subjects with varying AD severity, found that acute inflammation correlated with a twofold cognitive decline increase, and high-baseline TNF-α levels quadrupled the decline [98].”
BackgroundTNFα promotes proliferation of oligodendrocyte progenitors and remyelination
Arnett, H. A., Mason, J., Marino, M., Suzuki, K., Matsushima, G. K., & Ting, J. P.-Y. (2001) · Nature Neuroscience · doi:10.1038/nn738 · Cited by 1,012 · cited 1×
“…excitotoxicity, neuroinflammation, blood-brain barrier permeability [19], regulation of oligodendrocyte survival, myelin formation and repair [22], its excessive or dysregulated production can have detrimental effects on neuronal health, contributing to the development of neurodegeneration…”
BackgroundRegulation of tumour necrosis factor signalling: live or let die
Brenner, D., Blaser, H., & Mak, T. W. (2015) · Nature Reviews Immunology · doi:10.1038/nri3834 · Cited by 998
Differential Regulation of AMPA Receptor and GABA Receptor Trafficking by Tumor Necrosis Factor-α
Stellwagen, D., Beattie, E. C., Seo, J. Y., & Malenka, R. C. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.4486-04.2005 · Cited by 985 · cited 3×
“TNF-α modulates and influences many neuronal activities in the CNS, which include glutamatergic transmission [58–60] and gamma-aminobutyric acid (GABA) transmission [58,61,62], with an overall outcome of these alterations of an augmentation of excitatory synaptic transmission compared to inhibitory…”
BackgroundTumor necrosis factor alpha: A link between neuroinflammation and excitotoxicity
Olmos, G., & Lladó, J. (2014) · Mediators of Inflammation · doi:10.1155/2014/861231 · Cited by 730 · cited 1×
“TNF-α is primarily produced by microglia, astrocytes, and neurons in response to various stimuli [21].”
Background
Cited by
Targeting Microglia in Alzheimer’s Disease: Pathogenesis and Potential Therapeutic Strategies
Sun, Z., Zhang, X., So, K.-F., Jiang, W., & Chiu, K. (2024) · Biomolecules · doi:10.3390/biom14070833 · Cited by 71
“Numerous studies have demonstrated that individuals with rheumatoid arthritis (RA) and other systemic inflammatory diseases who utilize TNF-α blockers exhibit a reduced risk of developing dementia compared to the general population [106].”
BackgroundArfaei, R., Mikaeili, N., Daj, F., Boroumand, A., Kheyri, A., Yaraghi, P., Shirzad, Z., Keshavarz, M., Hassanshahi, G., Jafarzadeh, A., et al. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112328 · Cited by 27
Azizan, Z., Bazrgar, M., Bazgir, N., Moini, S. H., Ghaseminejad‐Kermani, S., Safa, K., Eshaghian‐dorcheh, A., & Harirchian, M. H. (2025) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.70269 · Cited by 10
The mTOR pathway: a common link between Alzheimer's disease and Down Syndrome
Wohlfert, A. J., Phares, J., & Granholm, A.-C. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13206183 · Cited by 6
“It has also been reported that TNF-α , an upstream modulator of mTOR, can influence the formation of A β plaques and NFTs [108–110].”
Background
Metadata
- Authors
- Plantone, D., Pardini, M., Righi, D., Manco, C., Colombo, B. M., & De Stefano, N.
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2023-12-26
- Volume
- 13
- Issue
- 1
- Pages
- 54
- ISSN
- 2073-4409 (ISSN-L)
- OpenAlex
- W4390272828
- Cited by
- 111
- References
- 33
- FWCI
- 5.55
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.